Does high risk mean high reward? Not necessarily, so say the pros on Wall Street.
Oncolytics Biotech, Inc. (USA) (OTCMKTS:ONCYF) announced that enrollment has commenced in a Phase Ib study of REOLYSIN® combined with standard doses of bortezomib (Kyprolis®) …
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that it has received notification from OTC Markets Group Inc.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that, following submission to the U.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that Dr.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced the encore presentation of findings from a post-hoc analysis examining the effects of icosapent ethyl (Vascepa®) on Apolipoprotein …
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that enrollment has been completed in a randomized Phase II study of REOLYSIN® in patients with previously treated advanced …
By Terry Chrisomalis Oncolytics Biotech, Inc. (USA) On July 6, 2015 shares of Oncolytics Biotech, Inc.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) announced that a series of oral and poster presentations are being made by the Company’s research collaborators at …
